相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib
Astrid A. M. van der Veldt et al.
ANTI-CANCER DRUGS (2010)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
Suzanne E. Dahlberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Michael L. Maitland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
P. Bono et al.
ANNALS OF ONCOLOGY (2009)
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
M. Scartozzi et al.
ANNALS OF ONCOLOGY (2009)
Hypertension and proteinuria: a class-effect of antiangiogenic therapies
Vincent Launay-Vacher et al.
ANTI-CANCER DRUGS (2009)
Rapid Development of Hypertension by Sorafenib: Toxicity or Target?
Benjamin D. Humphreys et al.
CLINICAL CANCER RESEARCH (2009)
Diagnosis and Management of Hypertension in Advanced Renal Cell Carcinoma: Prospective Evaluation of an Algorithm in Patients Treated with Sunitinib
A. Bamias et al.
JOURNAL OF CHEMOTHERAPY (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
Neeltje Steeghs et al.
CLINICAL CANCER RESEARCH (2008)
Angiogenesis factors and preeclampsia
Ralf Dechend et al.
NATURE MEDICINE (2008)
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Jeanine M. Roodhart et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors
M. M. Cooney et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hypertension as a predictive factor of Sunitinib activity
O. Rixe et al.
ANNALS OF ONCOLOGY (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypertension and targeted therapy Part 2: Small molecule inhibitors of VEGF
Simon Chowdhury et al.
TARGETED ONCOLOGY (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Hypertension and targeted therapy Part 1: Bevacizumab
Simon Chowdhury et al.
TARGETED ONCOLOGY (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Vascular endothelial growth factor-induced nitric oxide- and PG12-dependent relaxation in human internal mammary arteries - A comparative study with KDR and Flt-1 selective mutants
W Wei et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2004)
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
AV Chobanian et al.
HYPERTENSION (2003)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)